CanSino Biologics Inc. (6185.HK)
HKD 29.5
(2.97%)
HKD 29.5
(2.97%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 350.65 Million CNY | -48.26% |
| 2022 | 677.77 Million CNY | -22.59% |
| 2021 | 875.62 Million CNY | 413.52% |
| 2020 | 170.51 Million CNY | 943.65% |
| 2019 | 16.33 Million CNY | 92.35% |
| 2018 | 8.49 Million CNY | 423.03% |
| 2017 | 1.62 Million CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 355.41 Million CNY | 1.36% |
| 2024 Q2 | 359.58 Million CNY | 1.17% |
| 2023 Q2 | 454.43 Million CNY | -42.36% |
| 2023 FY | 350.65 Million CNY | -48.26% |
| 2023 Q4 | 350.65 Million CNY | -15.99% |
| 2023 Q3 | 417.37 Million CNY | -8.15% |
| 2023 Q1 | 788.34 Million CNY | 16.31% |
| 2022 Q2 | 1.18 Billion CNY | 5.96% |
| 2022 FY | 677.77 Million CNY | -22.59% |
| 2022 Q4 | 677.77 Million CNY | -23.02% |
| 2022 Q3 | 880.46 Million CNY | -25.92% |
| 2022 Q1 | 1.12 Billion CNY | 28.1% |
| 2021 Q4 | 875.62 Million CNY | 48.39% |
| 2021 Q1 | 340.19 Million CNY | 99.51% |
| 2021 Q2 | 517.39 Million CNY | 52.09% |
| 2021 Q3 | 590.09 Million CNY | 14.05% |
| 2021 FY | 875.62 Million CNY | 413.52% |
| 2020 Q4 | 170.51 Million CNY | 179.69% |
| 2020 FY | 170.51 Million CNY | 943.65% |
| 2020 Q2 | 26.01 Million CNY | 27.22% |
| 2020 Q3 | 60.96 Million CNY | 134.34% |
| 2020 Q1 | 20.44 Million CNY | 25.16% |
| 2019 Q4 | 16.33 Million CNY | 0.0% |
| 2019 FY | 16.33 Million CNY | 92.35% |
| 2019 Q2 | 11.86 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 FY | 8.49 Million CNY | 423.03% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q3 | 8.49 Million CNY | 0.0% |
| 2018 Q4 | 8.49 Million CNY | 0.0% |
| 2017 FY | 1.62 Million CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 12.19 Million HKD | -2774.937% |
| Grand Pharmaceutical Group Limited | 1.38 Billion HKD | 74.748% |
| Extrawell Pharmaceutical Holdings Limited | 7.26 Million HKD | -4726.648% |
| Wai Yuen Tong Medicine Holdings Limited | 308.09 Million HKD | -13.813% |
| Qianhai Health Holdings Limited | 431.78 Million HKD | 18.789% |
| Lee's Pharmaceutical Holdings Limited | 298.1 Million HKD | -17.628% |
| Essex Bio-Technology Limited | 62.82 Million HKD | -458.175% |
| Tongfang Kontafarma Holdings Limited | 98.26 Million HKD | -256.844% |
| PuraPharm Corporation Limited | 175.59 Million HKD | -99.694% |
| SSY Group Limited | 1.08 Billion HKD | 67.72% |
| JBM (Healthcare) Limited | 91.58 Million HKD | -282.875% |
| Jacobson Pharma Corporation Limited | 317.85 Million HKD | -10.319% |
| China Resources Pharmaceutical Group Limited | 35.09 Billion HKD | 99.001% |